
When the number of patients drop statistical uncertainty goes up and that might be the reason that Novo Nordisk failed to gain approval for its new insulin, Tresiba, in the US, according to several sources.
Data from the meta-analysis FDA based its rejection on shows that the patient population decreases dramatically as the study advances.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app